Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Wyeth respond to TNF blocker analysis

Amgen and Wyeth respond to TNF blocker analysis

5th June 2008

Amgen and Wyeth Pharmaceuticals have responded to an ongoing safety review into tumour necrosis factor (TNF) blockers and the possible link between these and the development of cancer.

According to a statement on Amgen’s website, the company has provided the US Food and Drug Administration (FDA) with information from groups’ adverse events databases.

It follows an association between the use of TNF blockers and the development of lymphoma and some other cancers in young adults and children, all of whom used the products (marketed as Cimzia, Remicade, Enbrel and Humira) to treat Crohn’s disease, juvenile idiopathic arthritis and other conditions.

Based on a preliminary review, the administration has decided to carry out further analyses of TNF blockers and their use in younger patients.

Amgen and Wyeth said it agreed with the FDA, which said prescribers and patients should always be aware of any possible risks before deciding on a course of treatment.

Meanwhile, this week saw Amgen publish data from its ongoing phase III trialsto support the continuing study of Vectibix (panitumumab).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.